Menu
Back to User profile » Professor Peter MA Calverley
Papers published by Professor Peter MA Calverley:
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset [Corrigendum]
Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2451-2452
Published Date: 3 October 2022
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1909-1920
Published Date: 22 August 2022
A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
Miravitlles M, Verhamme K, Calverley PMA, Dreher M, Bayer V, Gardev A, de la Hoz A, Wedzicha J, Price D
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:545-558
Published Date: 11 March 2022
FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
Bikov A, Lange P, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Yates JC, Vestbo J
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1135-1142
Published Date: 20 May 2020
Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
Calverley PMA, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2733-2744
Published Date: 2 December 2019
Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
Calverley PMA, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1297-1308
Published Date: 23 April 2018
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
Watz H, Bagul N, Rabe KF, Rennard S, Alagappan VKT, Román J, Facius A, Calverley PMA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:813-822
Published Date: 6 March 2018
Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial
Wise RA, Calverley PMA, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:605-616
Published Date: 14 February 2018
Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
Calverley PMA, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3391-3405
Published Date: 29 November 2017
The association of tidal EFL with exercise performance, exacerbations, and death in COPD
Aarli BB, Calverley PM, Jensen RL, Dellacà R, Eagan TM, Bakke PS, Hardie JA
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2179-2188
Published Date: 26 July 2017
The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
Eriksson G, Calverley PM, Jenkins CR, Anzueto AR, Make BJ, Lindberg M, Fagerås M, Postma DS
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1457-1468
Published Date: 15 May 2017
Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, Fagerås M, Postma DS
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:13-25
Published Date: 19 December 2016
Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease
Rodriguez-Roisin R, Tetzlaff K, Watz H, Wouters EF, Disse B, Finnigan H, Magnussen H, Calverley PM
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1973-1981
Published Date: 22 August 2016
Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
Calverley PM, Postma DS, Anzueto AR, Make BJ, Eriksson G, Peterson S, Jenkins CR
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:381-390
Published Date: 25 February 2016
Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR® trial
Dusser D, Wise RA, Dahl R, Anzueto A, Carter K, Fowler A, Calverley PM
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:133-145
Published Date: 20 January 2016
Roflumilast: a review of its use in the treatment of COPD
Wedzicha JA, Calverley PMA, Rabe KF
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:81-90
Published Date: 6 January 2016
A score to predict short-term risk of COPD exacerbations (SCOPEX)
Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:201-209
Published Date: 27 January 2015
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials
Rennard SI, Sun SX, Tourkodimitris S, Rowe P, Goehring UM, Bredenbröker D, Calverley PM
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:657-673
Published Date: 24 June 2014
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:375-382
Published Date: 20 June 2012